Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Aizant Drug Research Solutions Private Limited, is an unlisted private company incorporated on 22 November, 2005. It is classified as a private limited company and is located in Rangareddi, Telangana. It's authorized share capital is INR 26.00 cr and the total paid-up capital is INR 24.69 cr.
Aizant Drug Research Solutions's operating revenue range is INR 100 cr - 500 cr for the financial year ending on 31 March, 2022. It's EBITDA has increased by 426.72% over the previous year. At the same time, it's book networth has increased by 19.15%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
47.23%
66.71%
88.14%
26.37%
24.78%
18.86%
-3.39
3.16
3.72
6.86
9.05
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(5)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
The Karur Vysya Bank Limited
No. of Loans: 2
Total Amount : 16.6 cr
State Bank of India
No. of Loans: 1
Total Amount : 2.9 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Managing Director | Varma Srinivasa Rajasekara Rudraraju
Shareholder
|
01661426 | 19 years |
| Director | Nookala Venkata Satya Surya Lakshmi Narayana | 02572688 | 16 years |
| Director | Tirunelveli Padmanabhan Devarajan | 03473633 | 8 years |
| Director | Rudraraju Sneha | 09683892 | 1 years |
| Kmp | Srinivasa Sarma Rani | <HIDDEN> | 2 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| KURU CONSULTANTS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Andhra Pradesh |
| INCILIA THERAPEUTICS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| VIVOZANT BIOSCIENCES PRIVATE LIMITED |
Strike Off
|
0.0 | 1 | Telangana |
| AIZANT PHARMACEUTICALS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Andhra Pradesh |
| SANATIVE THERAPEUTICS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| AIZEN SIM6 PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| AIZEN ALGO PRIVATE LIMITED |
Active
|
2.1 Cr | 2 | Telangana |
| SARUDBHAVA FORMULATIONS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| ANKURA MEDICAL & RESEARCH CENTRE PRIVATE LIMITED |
Active
|
5.5 Cr | 1 | Telangana |
| SANDOR LIFE SCIENCES PRIVATE LIMITED |
Active
|
10.7 Cr | 1 | Telangana |
| MALLADI DRUGS AND PHARMACEUTICALS LIMITED |
Active
|
63.9 Cr | 1 | Tamil Nadu |
| PHASORZ TECHNOLOGIES PRIVATE LIMITED |
Active
|
57.9 Cr | 1 | Tamil Nadu |
| ALNICHE LIFESCIENCES PRIVATE LIMITED |
Active
|
1.3 L | 1 | Delhi |
The incorporation date of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED is 22 November, 2005
The authorized share capital of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED is INR ₹ 26.0 Cr.
The paid-up capital of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED is INR ₹ 24.7 Cr.
The registered address of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED is Sy No.172 /173, Apparel Park Road, Dulapally Vil. Dundigal Gandimaisamma Mdl, Medchal - Malkajgiri Hyderabad Rangareddi Telangana - 500100
The CIN number of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED is U24239TG2005PTC048133.
Expand
Delete
Collapse
See
details
